



August 30, 2012

Materials Licensing Section
U.S. Nuclear Regulatory Commission, Region III
2243 Warrenville Road, Suite 210
Lisle, Illinois 60532-4351

Re: Amendment to Esperion Therapeutics, Inc. License No: 21-32115

Greetings,

To reflect changes in Esperion Therapeutics, Inc. organization unrelated to performance, we request that Mark Spahr be removed from Esperion's NRC license 21-32115. Mr. Spahr's addition to Esperion's license was documented in amendment No. 2, NRC Material License 21-32115-02. The removal is effective immediately.

If you have any questions or if we can provide you with any additional information that would expedite your review, please contact RSO Mr. Clay Cramer at (734) 862-4842 or (734)-546-4606. Thank you very much, and we look forward to timely amendment of or license.

Sincerely,

A handwritten signature in black ink that reads "Roger Newton". The signature is written in a cursive, flowing style.



Roger Newton
President and CEO
Esperion Therapeutics, Inc.

46701 Commerce Center Drive
Plymouth, MI 48170

RECEIVED SEP 04 2012

Esperion Therapeutics
46701 Commerce Center Dr
Plymouth, MI 48170

29 AUG 2012



Materials Licensing Section
U.S. Nuclear Regulatory Commission, Region III
2243 Warrenville Road, Suite 210
Lisle, Illinois 60532-4351